Advisory Boards
The Scientific Advisory Board, the Ethics and Clinical Advisory, and the Portfolio Advisory Committee will advise the TBVAC-HORIZON consortium.
Members of the Scientific Advisory Board
Ann M. Ginsberg, M.D., Ph.D., is Deputy Director, TB Vaccines in the Global Health Division of the Bill & Melinda Gates Foundation. She has conducted and managed TB research and product development programs for 25 years, including 15 years leading and designing clinical strategy for development of TB vaccines and drug regimens for the developing world. Ann previously served as the Chief, Respiratory Diseases Branch, NIAID, NIH, as Director, Project Management at Merck Research Laboratories, as Chief Medical Officer at the Global Alliance for TB Drug Development, as Chief Medical Officer at Aeras and as Senior Technical Advisor at IAVI. In these roles, she oversaw the early clinical development program of Pretomanid and two recent, positive TB vaccine efficacy trials – of BCG revaccination and M72/AS01E. Ann has served on numerous national and international advisory committees on vaccines and global health, including the U.S. National Vaccine Advisory Committee. Her AB cum laude in Biology is from Harvard University, her PhD in Molecular Biology from Washington University and her MD from Columbia University. She was Board-certified in Anatomic Pathology.
Dr. Sam Behar is Professor of Microbiology and Physiological Systems at the University of Massachusetts Chan Medical School, where he studies immunity to Mycobacterium tuberculosis. Dr. Behar and the members of his lab have made important contributions to our understanding of immunity to tuberculosis including T cell priming, acquisition of effector function, and memory responses. By understanding mechanisms of host resistance to tuberculosis, including how T cell responses are coordinated and integrated in vivo, and how bacteria evade immunity, his ultimate goal is to inform vaccine design and testing.
Dr Ann Rawkins nee Williams
Members of the Ethics and Clinical Advisory:
Michèle Tameris, MBChB, is a South African who qualified as a medical doctor in 1980 at the University of Cape Town, followed by 20 years practicing in the state health services. In 2003 she joined the staff of South African Tuberculosis Vaccine Initiative (SATVI) within the University of Cape Town as a clinical researcher based at their field site in Worcester where she has been actively involved as principal or sub-investigator in 32 TB vaccine research trials of 10 novel candidates, as well as TB treatment and diagnostic trials. In 2022 she received ad hominem promotion to Chief Research Officer with the title of Associate Professor.
She received Wellcome Trust International Engagement Awards in 2012 and 2014 for two drama projects targeting respectively adolescents and the community at large. She is a core member of the Stop TB Working Group for new Vaccines.
Dr Norbert Stockhofe is qualified as veterinarian and working as senior veterinary pathologist at Wageningen Bioveterinary Research, part of Wageningen University & Research. Since over 30 years he is working on infectious diseases in farm animals and humans using target animal and biomedical animal models. He has participated in more than 10 EU projects on vaccine and infectious disease research. Since more than 25 years he is participating in animal experimentation comities and for nearly 10 years head of one Animal Welfare Body of Wageningen University & Research.
Members of the Portfolio Advisory Committee (PAC):
Dr Elly van Riet is a senior scientist at TBVI, using her 15 years of experience in several aspects of vaccine research, to move the development of safe, effective and affordable TB vaccines forward. She earned her MSc as an engineer in biotechnology at Wageningen University and Research Centre, followed by a Ph.D. in immunology at the Department of Parasitology, Leiden University Medical Centre, both in The Netherlands. She has worked on vaccine development ever since, first as a postdoc at the Leiden Academic Centre for Drug Research (The Netherlands). She was granted a postdoctoral fellowship by the ‘Japan Society for the Promotion of Science’ at Research Center of the National Institute of Infectious Diseases (Tokyo, Japan). In 2013 she joined Intravacc, a Dutch organization developing vaccines from discovery to phaseI/II clinical trials, as head of the department Clinical Development and later as Program Manager of Innovation, Program Manager of Bacterial Vaccines and Vice President R&D.
Dr Barry Walker is former Vice President of Preclinical Development (Aeras, USA), and previously, Principal Scientist at the National Institute for Biological Standards and Control, NIBSC, UK. He has over 30 years’ experience in vaccine discovery and translational development of biologicals, with 20 years’ experience in a regulatory environment. As Vice President Preclinical Development at Aeras he focussed and implemented the strategy for the clinical immune studies and vaccine development programme for Aeras for over 4 years and brought 4 new vaccine strategies from concept to clinical development. Prior to this he was Principal Scientist and PI at the Immunology and Cellular Immunity Section and the Bacteriology Division at NIBSC. In these roles he has also advised on strategic implementation of specific programmes funded by the EC, BMGF and the NIH. Currently acting as an independent scientific consultant translational development of biologicals with an honorary position at University of Surrey.
Prof. Dr Gideon Kersten is a vaccinologist with over 35 years of experience in vaccine development. His special interests are in characterization and formulation of vaccines and other biologicals. At Institute for Public Health in the Netherlands (RIVM) he was involved in the development of new vaccines and improving existing ones. These included vaccines against polio, influenza, RS virus, Neisseria meningitidis type B and pertussis. He was responsible for formulation development and vaccine characterization. Since 2012 he holds a special professorship in vaccine development at the Leiden Academic Center for Drug Research . In 2017 he became Chief Scientific Officer of Intravacc. In 2020 he joined Coriolis Pharma, a contract research organization located near Munich and dedicated to the characterization and formulation of biologics. At Coriolis he is a scientific reviewer and scientific advisor.
Dr Simon Clark is Principal Scientist in the Pre-clinical team of the Vaccine Development Evaluation Centre at the UK Health Security Agency, Porton Down, UK.
Dr. Simon Clark provides scientific direction to the TB research programme which aims to develop and utilise aerosol-challenge in-vivo models to identify vaccine and/or therapeutic candidates. Dr. Clark has over 20 years of experience in the pre-clinical evaluation of interventions against human diseases (including TB & NTM infections). Dr. Clark has established and refined aerosol generation and delivery systems allowing characterisation of pathogens in aerosols, and infection. He leads in vivo microbiologists, immunologists and aerobiologists and has collaborated globally with the majority of the key developers.
Dr Philip Hogarth, Medical and Health products Regulatory Agency (MHRA), is an immunologist, gaining his PhD at the Liverpool School of Tropical Medicine in 1997. After postdoc positions at Bristol University, he joined APHA in 2001 to recruit/lead a group developing mouse models of bovine TB: screening novel vaccines, vaccine regimens and administration routes to inform cattle infection models. A particular area of focus was mechanisms and correlates of immunity induced by BCG and BCG prime-boost approaches. Using high parameter flow cytometry, Phil’s team pioneered UK work on the role of lung CD4 T cell tissue-resident memory cells to BCG. The group defined and translated relevant immune parameters/assays from murine to cattle vaccination/infection models, developing novel reagents and assays where required. In 2018, Phil moved into a science:policy interface role at Defra as TB science Subject Matter Expert, developing R&D strategies in response to the 2018 Godfray Review on behalf of England and the Devolved Administrations on Scotland & Wales. In 2020 he returned to APHA as TB Lead Scientist, leading the TB Portfolio in R&D, Surveillance, Field and Data Sciences. During his tenure, Phil introduced significant advancements to statutory bTB confirmation and surveillance, implementing molecular disease confirmation, and WGS/geographic-linked phylogenetic investigation for frontline outbreak characterisation He also transitioned CattleBCG and the BCG compatible DIVA test from research projects into regulatory field trials in preparation for Marketing Authorisations and rollout in England & Wales. In September 2023, Phil accepted a new role, as Head of Vaccines R&D at the MHRA, where he leads a diverse division with 7 research groups which includes TB.